Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

BACKGROUND: This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of the mammalian target of rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer. METHODS: Women with measurable recurrent or persistent endometrial cancer and documented disease pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, N, McMeekin, D S, Schwartz, P E, Sessa, C, Gehrig, P A, Holloway, R, Braly, P, Matei, D, Morosky, A, Dodion, P F, Einstein, M H, Haluska, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619076/
https://www.ncbi.nlm.nih.gov/pubmed/23403817
http://dx.doi.org/10.1038/bjc.2013.59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619076/
https://www.ncbi.nlm.nih.gov/pubmed/23403817
http://dx.doi.org/10.1038/bjc.2013.59

Ejemplares similares